公开(公告)号：US20240141437A1

公开(公告)日：2024-05-02

申请号：US18327305

申请日：2023-06-01

Applicant: Genentech, Inc.

Inventor： Sanjeev MARIATHASAN ,  Chi Yung YUEN ,  Zoe June Fergusson ASSAF ,  Carlos Ernesto BAIS ,  Romain Francois BANCHEREAU

IPC: C12Q1/6886 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12Q1/686 ,  C12Q1/6869 ,  A61K39/00

CPC classification number: C12Q1/6886 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2827 ,  C12Q1/686 ,  C12Q1/6869 ,  A61K2039/505 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158

Abstract: The invention provides methods and compositions for treating urothelial carcinoma in a patient, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the patient as a neoadjuvant or an adjuvant therapy based on the presence or level of ctDNA in a biological sample obtained from the patient. Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating urothelial carcinoma in a patient.